Cargando…

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma

Detalles Bibliográficos
Autores principales:	Atrash, Shebli, Robinson, Myra, Slaughter, Daniel, Aneralla, Amanda, Brown, Taylor, Robinson, Jordan, Ndiaye, Ami, Sprouse, Chelsea, Zhang, Qing, Symanowski, James T., Friend, Reed, Voorhees, Peter M., Usmani, Saad Z., Bhutani, Manisha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224422/ https://www.ncbi.nlm.nih.gov/pubmed/30410066 http://dx.doi.org/10.1038/s41408-018-0144-x

Ejemplares similares

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma
por: Foureau, David M., et al.
Publicado: (2020)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Retrospective Review of Outcomes of Multiple Myeloma (MM) Patients With COVID-19 Infection (Two-Center Study)
por: Ehsan, Hamid, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma
por: Atrash, Shebli, et al.
Publicado: (2021)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Recent Advances in the Management of Smoldering Multiple Myeloma
por: Madhira, Bhaskara Reddy, et al.
Publicado: (2020)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
por: Zanelli, Magda, et al.
Publicado: (2021)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
por: Lussier, Tyler, et al.
Publicado: (2021)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib
por: Atrash, S, et al.
Publicado: (2015)

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma
por: Markus, Efrat, et al.
Publicado: (2020)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Amyloid arthropathy in smoldering myeloma: Do not take it lightly
por: Muchtar, Eli, et al.
Publicado: (2021)

Dynamic follow‐up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
por: Gran, Charlotte, et al.
Publicado: (2020)

Prevalence, incidence and survival of smoldering multiple myeloma in the United States
por: Ravindran, A, et al.
Publicado: (2016)

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case
por: Ghanem, Sassine, et al.
Publicado: (2016)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis
por: Bouattour, Nadia, et al.
Publicado: (2020)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

Kidney transplantation for active multiple myeloma or smoldering myeloma: a case–control study
por: Kormann, Raphaël, et al.
Publicado: (2019)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

In vivo confocal microscopy of verticillata-like paraproteinemic keratopathy in a patient with monoclonal gammopathy of uncertain significance evolving into smoldering multiple myeloma
por: Chierego, Chiara, et al.
Publicado: (2019)

Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia
por: Atrash, Shebli, et al.
Publicado: (2017)

Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report
por: Troppmann, Martina, et al.
Publicado: (2012)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Application of Next-Generation Sequencing for the Genomic Characterization of Patients with Smoldering Myeloma
por: Manzoni, Martina, et al.
Publicado: (2020)

Eosinophilic Fasciitis and Smoldering Multiple Myeloma: An Exceptional Association in Young Adults
por: Jabbouri, Rajaa, et al.
Publicado: (2022)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hbb5tvjgoobum8t0ujqhcphu1v